DNDi aims to:

  • Make treatments safer, shorter, and more affordable and effective for all forms of leishmaniasis.
  • In the short term, better treatment regiments are being developed using existing drugs.
  • In the long term, the goal is to develop an entirely new generation of all-oral drugs.

 

The current portfolio for both visceral and cutaneous leishmaniasis includes:

Research

Discovery

Aminopyrazoles
CF series
Daiichi Sankyo Hit-to-lead
DNDI-5421 & DNDI-5610
Leishmaniasis Hit-to-lead
Leishmaniasis L205 Series
NTD Drug Discovery Booster Hit-to-lead
Screening

Translation

Translation

CpG-D35 for CL
DNDI-6148
DNDI-0690
DNDI-5561
GSK3186899/DDD853651
GSK3494245/DDD1305143

Development

Development

Miltefosine + paramomycin combination (Africa)
New CL combination
New treatments for HIV/VL
New treatments for PKDL
New VL treatments (Latin America)

Implementation

Implementation

SSG&PM (East Africa)
New VL treatments (South Asia)

 

For more details on each project, see DNDi‘s Global Portfolio